MYB oncoproteins: emerging players and potential therapeutic targets in human cancer

Ylenia Cicirò and Arturo Sala

Abstract
MYB transcription factors are highly conserved from plants to vertebrates, indicating that their functions embrace fundamental mechanisms in the biology of cells and organisms. In humans, the MYB gene family is composed of three members: MYB, MYBL1 and MYBL2, encoding the transcription factors MYB, MYBL1, and MYBL2 (also known as c-MYB, A-MYB, and B-MYB), respectively. A truncated version of MYB, the prototype member of the MYB family, was originally identified as the product of the retroviral oncogene v-myb, which causes leukaemia in birds. This led to the hypothesis that aberrant activation of vertebrate MYB could also cause cancer. Despite more than three decades have elapsed since the isolation of v-myb, only recently investigators were able to detect MYB genes rearrangements and mutations, smoking gun evidence of the involvement of MYB family members in human cancer. In this review, we will highlight studies linking the activity of MYB family members to human malignancies and experimental therapeutic interventions tailored for MYB-expressing cancers.

Introduction
Vertebrate MYB genes encode transcription factors related to the v-myb oncogene, the transforming gene of avian retroviruses causing myelomas and lymphomas in birds. AMV was originally identified as a virus that induces a disease in chickens similar to acute myelogenous leukaemia in humans. The v-mybAMV oncogene product, a 45 kDa protein, was proved to be a truncated version of vertebrate MYB, the 75 kDa product of the proto-oncogene MYB, mainly expressed in haematopoietic tissues. The v-myb oncogene was also found fused to a second oncogene, v-ets, in the E26 retrovirus that cause avian erythroblastosis. Invertebrates carry only one MYB gene which, from a phylogenetical and functional point of view, is equivalent to vertebrate MYBL2. There is no homologue of the MYB gene in nematodes, although distantly related genes, such as Cdc5 and SNAPc, have been identified in Caenorhabditis elegans.

In humans and other mammals, the transcription factor MYB (encoded by MYB) is the prototype member of the family, which includes MYBL1 (encoded by MYBL1) and MYBL2 (encoded by MYBL2). Although similar in structure, the different MYB proteins interact with unique co-factors and their expression is often nonoverlapping, suggesting that they might have distinct biological roles. All MYB family members recognise and bind the same DNA consensus sequence [PyAAC(G/T)G] to transactivate gene expression. This motif, firstly identified by the
Klempnauer group using DNA footprinting assays, is known as the canonical MYB-binding site (MBS)\textsuperscript{17}. The sequence was later confirmed to be present, and bound by v-myb, in the promoter region of the first MYB-target gene identified in vertebrates, mim-1\textsuperscript{18}. With the development of more advanced genomic technologies, different groups attempted the identification of MYB target genes at the global level. The Ness team found the c-MYB protein bound to over 10,000 promoters in the cancer breast cell line MCF-7, and validated known MYB target genes involved in the cell cycle, such as MYC and CCNB1, or identified new MYB target genes involved in stemness and transcription control such as JUN, KLF4, NANOG, and SND1\textsuperscript{19}. Another study by the Gonda lab identified genes regulated by MYB in mouse myeloid progenitor cells. This study not only confirmed that MYB positively regulates promoters of key cell proliferation genes, such as Myc, but it can also work as a transcriptional repressor. Indeed, several key regulators of myeloid differentiation such as Runx1, Pa.1, Jund and Cebp were strongly suppressed by exogenous expression of MYB, suggesting a mechanism used by the transcription factor to suppress differentiation and promote self-renewal\textsuperscript{20}. A selection of MYB target genes that have been shown to mediate physiological functions in normal or disease contexts is shown in Table 1.

The transcriptional activity of MYB proteins is regulated either positively or negatively by co-factors; cellular proteins physically interacting with the different MYB family members are indicated under their protein structures in Fig. 1. Structure–function relationships have been largely inferred by studying the prototype member of the family, MYB (c-MYB). For example, the TAD domain confers transactivating activity to MYB by recruiting CREB-binding domain protein (CBP) and p300\textsuperscript{21,22}. The CAAT enhancer-binding protein (C/EBP) family member NF-M cooperates with MYB in transcriptionally activating the mim-1 promoter through an adjacent
DNA-binding site and it is also co-activated by CBP in a Ras-dependent manner, suggesting that CBP might work by functionally linking MYB and NF-M\(^2\). Indeed, NF-M has been shown to affect the MYB-C/EBP interaction by disrupting the N-terminal region within the repeat domain R1 (amino acids 47–71), enhancing MYB oncogenic activity\(^2\). MYB can cooperate, cross-regulate and compete with other transcription factors, such as members of the C/EBP family, the ETS family, and GATA1\(^2\)–\(^4\). Recently, it has been shown that in ALL patients aberrant recruitment of the histone acetyl transferase CBP/p300 by MYB in the enhancer region of the protooncogene TAL1 occurs via the formation of de novo MYB-binding elements\(^2\). Alterations of MYB family genes in human cancer and experimental therapeutic approaches

MYB family members are often aberrantly expressed in human cancers, suggesting that they could be important for tumour initiation and/or maintenance. Since MYB proteins are essential for key cellular processes such as growth, differentiation and survival, it is likely that genomic mutations or alterations of gene expression might contribute to oncogenesis. Broadly expressed transcription factors are considered unsuitable therapeutic targets since their inactivation or downregulation could be detrimental to organism homoeostasis. Furthermore, it is inherently difficult to block the interaction of transcription factors with DNA using small molecules. Despite these caveats, therapeutic approaches aiming at inhibiting MYB oncoproteins, or their target genes, in cancer are under investigation in preclinical and clinical studies.

In the following paragraphs, we discuss studies in which MYB family members have been implicated in forms of human cancer. We also highlight laboratory experiments, or clinical trials, in which MYB, or MYB-regulated genes, have been targeted for therapeutic purposes.

**MYB**

Disruption of MYB causes embryonic lethality due to the failure of foetal hepatic haematopoiesis\(^2\). The key role

### Table 1  Selected MYB target genes.

| Target gene | Protein                                      | MYB member | References |
|-------------|----------------------------------------------|------------|------------|
| ATR         | Ataxia telangiectasia Rad3-related protein   | MYB        | 43         |
| BCL2        | B-cell lymphoma 2                            | v-Myb, MYBL2, MYB | 137,198,199 |
| BIRC5       | Survivin                                     | MYBL2, MYB | 201,200,201 |
| CCNA2       | Cyclin A2                                    | MYBL2      | 149,202    |
| CCNB1       | Cyclin B1                                    | MYB        | 19,23,203  |
| CCND1       | Cyclin D1                                    | MYBL2      | 131,204    |
| CCNE1       | Cyclin E1                                    | MYB        | 205,206    |
| CD34        | Haematopoietic progenitor cell antigen CD34   | MYB        | 207–209    |
| CDK1        | Cyclin-dependent kinase 1                    | MYBL2, MYB | 42,44,202  |
| CDK2        | Cyclin-dependent kinase 2                    | MYBL2      | 210        |
| CDK6        | Cyclin-dependent kinase 6                    | MYB        | 211        |
| CLU         | Apolipoprotein J/Clusterin                   | MYBL2      | 132,134,212 |
| CXCR4       | C-X-C chemokine receptor type 4              | v-Myb, MYB | 10,213     |
| IGF1R       | Insulin-like growth factor 1 receptor        | MYB        | 106,107,109,113 |
| KIT         | (c-)KIT/CD117                                | MYB        | 119,214,215 |
| MIM1        | Mitochondrial import protein 1               | v-Myb, MYB | 18,216,217  |
| MYC         | (c-)MYC                                      | MYBL2, MYB | 19,20,138,210,218 |
| NCAF1H      | Non-SMC Condensin I Complex Subunit H        | MYBL2      | 169        |
| PLK1        | Polo-like kinase 1                           | MYBL2      | 157,159,202 |
| TAL1        | T-cell acute lymphocytic leukaemia protein 1 | MYB        | 27         |
| VEGF        | Vascular endothelial growth factor           | MYB        | 118        |

---

**Notes:**

1. Cicirò, A., Sala, A. (2021). *Oncogenesis* 10, 1–10.
2. Cicirò, A., Sala, A. (2021). *Oncogenesis* 10, 1–10.
of the MYB gene product in mammalian haematopoiesis is also indicated by its ability to regulate the expression of foetal haemoglobin and requirement for the maturation of T and B lymphocytes. Although prevalently expressed in haematopoietic cells, MYB expression is detected also in neural tissues, as well as in colonic crypts and breast cells.

MYB, similarly to the ubiquitous member of the family MYBL2, regulates cyclin-dependent kinases (Cdks) expression and activity, essential for cell duplication. MYB autoregulates its own expression and is engaged in positive and negative regulatory loops with cyclins and Cdks, in both the G1 and G2 phases of the cell cycle.

**MYB alterations in cancer**

Genetic mutations and augmented expression of MYB have been firstly noted in leukaemic cells, and only relatively recently in solid cancers. Overexpression of wild type MYB is insufficient for full transformation of human epithelial cells, supporting the hypothesis that it promotes tumourigenesis only in combination with additional genetic alterations.

The first recurrent genomic rearrangements of the MYB locus were evidenced in acute T cell leukaemia, in which MYB overexpression is caused by gene duplication or translocation, juxtaposing strong enhancers from other genomic locations. Summarising the information present in literature, it is possible to group MYB oncogenic alterations into three classes: overexpression, fusion with partner genes, and ectopic binding of the MYB oncoprotein to enhancer sequences caused by somatic mutations (i.e. TAL1 enhancer). MYB gene amplification and overexpression have been observed in acute myeloid leukaemia (AML), non-Hodgkin lymphoma, colorectal cancer, and breast cancer. Fusion with partner genes is mainly observed in solid tumours, as discussed in detail in the following sections.

MYB genomic alterations have been detected in multiple forms of human cancer, suggesting a causative role. Therefore, numerous studies have been conducted in which inhibition of MYB, or of its downstream genes, has been used as a potential therapeutic strategy. Preclinical studies and actionable MYB target genes are summarised in Table 2.

**MYB and leukaemia** In a cluster of acute lymphoblastic leukaemia (ALL) patients, mutations of the TAL1 enhancer create ex-novo MYB-binding sites. The leukaemias arising in these patients show MYB-dependency consequential to the aberrant activation of the TAL1 oncogene by MYB. Through genomic screening of an independent set of 107 individuals with T cell ALL (T-ALL) and 12 T-ALL cell lines, Lahortiga et al. detected duplication of MYB in 9 of 107 (8.4%) cases and in five different cell lines. The flanking genes HBSIL and AHI1 were duplicated in some patients, but the commonly duplicated region covered only the MYB gene. The duplication is associated with a threefold increase in MYB expression, and its knockdown initiates T cell differentiation. Thus, MYB duplications may be leukemogenic in a subset of T-ALL patients.

In acute basophilic leukaemia (ABL) the MYB locus is fused to another gene encoding the transcription factor GATA1. This rare subtype of acute myeloblastic leukaemia is characterised by the t(X;6)(p11;q23) translocation, leading to decrease or loss of GATA1 (located on chromosome X) expression. Mice transgenically expressing the MYB–GATA1 fusion develop myelodysplasia and leukaemia when endogenous, wild-type GATA1 expression is concurrently downregulated. Ducassou and co-workers showed that the fusion promotes not only haematopoietic progenitor cell self-renewal, but also induces a bias toward granulocytic differentiation, consequently to sensitisation towards NGF- and IL-33-induced differentiation. The skewing towards basophilic differentiation was confirmed in primary human CD34-positive stem/progenitor cells, where the basophilic markers CD203c and FcεRI were activated after MYB–GATA1 expression. In vivo experiments using NSG mice led to conclusive evidence that basophilic differentiation is a

---

**Table 2  Preclinical and clinical therapeutic strategies based on inhibition of MYB or actionable MYB-target genes.**

| Treatment          | Target   | Cancer type       | References |
|--------------------|----------|-------------------|------------|
| AT7519, BE-09- LNS53 (CDK) | CDKs     | ER + BC           | 60         |
| ATRA               | MYB      | ACC               | 111        |
| Celastrol          | MYB-C/ EBPβ-p300 | AML             | 67         |
| Mebendazol        | MYB      | AML               | 69         |
| miR-200b/c        | EMT markers | ER + BC         | 54         |
| Monensin A        | MYB      | AML, ACC          | 110        |
| MYBMIM            | MYB-CBP/p300 | AML              | 71         |
| Naphthol AS-E phosphate | MYB-C/KIX(p300) | Leukaemia   | 68         |
| Plumbagin         | MYB/p300 | AML               | 70         |
| TetMYB vaccine    | MYB      | CRC, ACC          | 81         |
| VX-970            | ATR      | ACC               | 43         |
| Figitumumab       | IGFR     | ACC               | 109        |
| Linsitinib        | IGFR     | ACC               | 112        |

*ATRA all trans retinoic acid, ACC adenoid cystic carcinoma, AML acute myeloid leukaemia, CDKs cyclin-dependent kinases, CRC colorectal cancer, EMT epithelial mesenchymal transition, ER + BC oestrogen receptor positive breast cancer.*
direct consequence of MYB-GATA1 expression, rather than loss of endogenous GATA1. The increased responsiveness to IL-33 could contribute to the leukaemic phenotype, as previously observed in other myeloproliferative malignancies. Thus, MYB-GATA1 might promote cell growth, self-renewal and leukaemic transformation of basophilic progenitor cells.

A case report described a Philadelphia-negative myeloproliferative neoplasm (Ph-MPN) with an uncommonly rapid leukaemic progression, linked to JAK2V617F mutation. This primary myelofibrosis (PMF)-patient developed a peculiar chromosomal rearrangement resulting in a fusion involving EWSR1 and MYB. There are only a few reports of fusion of EWSR1 in leukaemia, whereas it is common in soft tissue sarcoma. EWSR1 is a FET (FUS, EWS, TAF15) family member whose function is to regulate transcription and mRNA splicing. Therefore, it seems reasonable to speculate that the EWSR1-MYB fusion could lead to dysregulated MYB transcriptional activity. Indeed, expression of the MYB target gene BCL2 was deregulated in EWSR1-MYB positive PMF, suggesting that molecular alterations involving MYB could increase disease risk in PMF patients.

AML is the most common form of acute leukaemia in adults. Although recent advances in genomic characterisations have shed some light on the molecular patterns involved in this cancer, the 5-year survival rate is <70% in children and 35% in adults. AML is a heterogeneous disease, often characterised by the presence of gene fusions or recurrent mutations in a set of driver genes. Genomic rearrangements involving the MLL gene, such as MLL–AF4 t(4;11)(q21;q23); MLL–AF9; t(9;11)(p22;q23); MLL–ENL; t(11;19)(q23; p13.3); MLL–AF10 t(10;11)(p12;q23) or MLL–AF6 t(6;11)(q27;q23) are associated with a very aggressive form of leukaemia. MYB has been shown to be a key downstream effector of MLL fusion oncoproteins, suggesting that it could be a target for therapeutic interventions. Since, as mentioned before, targeting transcription factors with small molecule inhibitors is difficult, the focus has been directed towards proteins that work as co-activators in the MYB network. p300 is a MYB transcriptional co-activator, required for leukaemogenesis. The small molecule inhibitor Celastrol, a triterpenoid, was used to disrupt the MYB/p300 interaction, therefore interrupting MYB signalling in leukaemic cells. Celastrol did not change MYB expression but inhibited the interaction of the transactivation domain of MYB with the KIX domain of p300. Accordingly, Celastrol strongly inhibited MYB-dependent transcriptional activation of target genes. Celastrol enhanced survival of mice transplanted with patient-derived HoxA9/Meis1-driven AML, confirming that targeting MYB transcription function could be an effective strategy in this leukaemia. Another compound used to disrupt the interaction between MYB and p300, Naphthol AS-E phosphate, inhibited the expression of the MYB gene itself, as well as that of several MYB-target genes, inducing myeloid differentiation and apoptosis. The negative effect of Naphthol AS-E phosphate on MYB gene expression could be a consequence of the block of MYB gene autoregulation. Nicolaides et al. showed that human MYB maintains high levels of its expression through an autoregulatory mechanism involving MYB-binding sites in the 5′ flanking region of the MYB gene itself.

The anti-helminth agent mebendazole exhibited anti-cancer activity in AML human cell lines by interfering with MYB activity. Short-term exposure to the drug induced changes in the expression level of MYB-regulated genes in cells expressing the MLL-AF9 fusion oncoprotein. Expression of the MYB oncoprotein was drastically reduced in the presence of low concentrations of the drug in all cell lines analysed, whereas MYB mRNA levels were only reduced after exposure to very high mebendazole concentrations, and only in a few of the cell lines. This suggested that the drug acts mainly at the protein level. Indeed, inhibition of the proteasome reversed MYB protein loss, demonstrating that mebendazole causes proteasomal degradation of MYB by interfering with the heat shock protein 70 (HSP70) chaperone system. Importantly, mebendazole impaired AML cancer progression in vivo.

5-hydroxy-2-methyl-1,4-naphthoquinone (also known as plumbagin) has been shown to target the transcriptional-activating domain (TAD) of MYB. By using the MYB TAD fused to the Gal4 DBD, the Klempnauer group observed that plumbagin inhibits transcription of a reporter gene containing GAL4-binding sites. Increasing the dosage of ectopically expressed p300, progressively antagonised the effect of plumbagin, demonstrating that the drug interfered with the p300–MYB interaction in AML cells.

Recently, a peptidomimetic approach to block the activity of MYB was developed by designing an inhibitory peptide called MYBMIM. The MYBMIM inhibitory effect is caused by its ability to disrupt the MYB:CBP/p300 complex. MYBMIM directly binds to the KIX domain of CBP with an affinity similar to the naïve complex, causing its disassembly and reduced MYB-dependent expression of genes whose enhancers are occupied by it. NOD-scid mice engrafted with leukaemia cells treated with the peptide showed significant reduction of cancer burden, which was caused by mitochondrial apoptosis. Furthermore, ChIP analysis revealed a marked loss of the epigenetic mark H3K27ac on super-enhancers regulated by acetylation driven by p300:CBP, and consequent reduced expression of key MYB-regulated genes such as MYC and BCL2.
MYB and paediatric low-grade gliomas (PLGGs)

PLGGs typically present gene fusions, especially related to component of the MAPK pathway, such as BRAF. MYB rearrangements have been recently discovered in the context of whole-genome sequencing (WGS) and/or RNA-sequencing (RNA-seq) of 249 samples of PLGGs, leading to the identification of recurrent MYB-QKI fusions in angiocentric gliomas. MYB fused to the RNA-binding protein QKI confers oncogenic properties using three distinct mechanisms. Firstly, the alteration results in the translocation of a super enhancer located in the 3’ untranslated region of QKI upstream the MYB promoter, resulting in its activation. Secondly, the MYB-QKI fusion protein acts as transcription factor, binding and activating the MYB promoter through a positive feedback loop. Thirdly, hemizygous loss of QKI expression caused by the rearrangement of its locus contributes to oncogenesis since it functions as a tumour-suppressor gene. Gene-set enrichment analysis (GSEA) revealed that the expression of MYB-QKI fusion was associated with MYB signature genes. MYB protein structure and its modifications found in tumours are fundamental for its transforming ability. In fact, as already mentioned above, full-length MYB is not endowed with a strong oncogenic activity in vitro, whereas C-terminal truncations are required for its activation. MYB-QKI breakpoints in MYB intron 9–15 result in C-terminal truncation and oncogenic activation of MYB.

MYB and colorectal cancers are characterised by MYB overexpression, which is associated with tumour aggressiveness and poor prognosis. MYB overexpression in colon cancer is a consequence of mutations in intron 1 regulatory sequence. Given the broad presence of the oncoprotein in this cancer, investigators in the Australian Peter MacCallum Cancer Centre engineered a vaccine against the MYB antigen called TetMYB. It is composed of an inactivated MYB protein flanked by the tetanus toxin T cell epitopes cloned into the pVAX1 plasmid vector. The immunotherapeutic role of the pVAX1-Tet-human MYB DNA vaccine was investigated in colon and adenoid cystic carcinoma (ACC) patients, also in combination with the anti-PD-1 antibody BGB-A317 to assess safety and maximum tolerated dose (MTD) in a first-in-human clinical trial. This approach should overcome limitations caused by epitope/MHC restriction when targeting an endogenous antigen, as its application will not depend upon a need to match the patient’s MHC subtype. The trial, if successful, could pave the way for vaccine treatment not only of colorectal cancers or ACC, but also other MYB-expressing cancers. This clinical trial is based upon preclinical studies of the same Australian group in mice transplanted with MC38 colon adenocarcinoma cells expressing high levels of MYB. Breaking peripheral tolerance with the vaccine strategy enhanced anti-tumour immunity mediated by both CD4+ and CD8+ T cells, without insurgence of autoimmunity, causing a significant suppression of MC38 cancer growth. MYB alterations have been also observed in pancreatic cancer, where it has been shown to interact with genes required for proliferation, survival and metastasis.

MYB and breast cancer

MYB has been found bound to more than 10,000 promoters in MCF-7 breast cancer cells and recognised as a key activator of downstream targets, including genes involved in cancer progression and metastasis, such as cyclooxygenase-2 (COX-2), BCL2, BCLXl, JUN, KLF4, NANOG, MYC, and CXCR4. Breast cancer is a heterogeneous disease with a clinical outcome strictly determined by molecular profiles. Over 70% of human breast cancers are oestrogen receptor-positive (ER+) and express MYB. Gonda and colleagues reported for the first time that inhibition of MYB expression severely impairs the proliferation of ER+, but not ER−, breast cancer cell lines. The relationship between MYB and ER is also indicated by the expression of MYB in normal, ER+ murine mammary epithelial cells, suggesting a salient role of the MYB transcription factor in mammary cell proliferation and tumour development in the human and mouse systems.

ER+ breast cancer benefits from endocrine therapy (ET), which can reduce local and distant cancer recurrence and mortality rate. ET can be administrated as neoadjuvant, adjuvant or palliative treatment and includes aromatase inhibitors, selective ER modulators (SERMs) such as tamoxifen, and antagonists such as fulvestrant.

In ER+ve breast cancer patients, MYB expression is oestrogen-dependent, since it was observed that MYB mRNA levels were 5-fold higher 24 h after stimulating breast cancer cells with beta-estradiol, suggesting a strong correlation between the proto-oncogene expression and ER status in cancer. MYB expression in ER+ve breast cancer cells is regulated at the level of transcriptional elongation, leading to the hypothesis that CDK9 inhibitors could be used to indirectly target MYB in this cancer. Indeed, CDK9 inhibition resulted in apoptotic death of breast cancer cell lines, accompanied by dose-dependent inhibition of the MCL-1 gene and protein expression. CDK9 inhibitors also impaired cell proliferation and cell cycle progression, inducing arrest at both the G1/S and G2/M phases of the cell cycle. Moreover, this led to the downregulation of MYB target genes involved in cell cycle progression such as CCNB1 and CCNE1, which was reversed by ectopic expression of MYB.

Breast cancer patients often develop resistance to treatment. Activation of epithelial–mesenchymal transition (EMT) is a mechanism by which breast cancer cells acquire...
resistance to targeted therapies\textsuperscript{91}. Micro-RNAs have been implicated in the EMT process, particularly the miR-200 family\textsuperscript{92,93}. Following ectopic over expression of miR-200b/c in drug-resistant cells, MYB expression levels decreased, indicating that it is a target of miR-200s. After silencing MYB in an ER\textsuperscript{+}ve breast cancer cell line refractory to tamoxifen therapy, the authors of the study observed that the EMT markers vimentin, ZEB1, and ZEB2 were down-regulated, further supporting the hypothesis that MYB is involved in EMT and drug resistance in breast cancer. Indeed, as expected, breast cell line sensitivity to tamoxifen therapy was increased after inhibiting MYB expression\textsuperscript{94}.

**MYB and ACC** Stenman and colleagues discovered the translocation t(6;9)(q23;p23) as a genomic hallmark of ACC\textsuperscript{95}. The translocation results in the fusion of the carboxyl-terminus of the MYB oncoprotein to five amino acids (SWYLG) encoded by the last exon of NFIB (Fig. 2)\textsuperscript{95,96}. ACC is characterised by the presence of the MYB-NFIB fusion gene in 30–86\% of cases, depending on the study\textsuperscript{97,98}. An important consequence of chromosomal rearrangements in ACC is the translocation of strong enhancers near the MYB, or MYBL1, locus, which activates their transcription\textsuperscript{99}. Rearrangements of the MYB locus have been observed in ACCs of the breast, lungs or glands in different body locations and in cylindromas, suggesting that MYB activation is frequent in exocrine gland tumours\textsuperscript{98,100–102}. Another consequence of the chromosomal translocations detected in ACC and other gland tumours is, in some cases, loss of genetic material. In this regard, Mitani and colleagues theorised that two genetic events drive ACC pathogenesis: one involves the generation of fusion genes resulting from reciprocal translocation between chromosome 6q and 9p or other partners, and the other event constitutes a loss of genetic material, denoting the presence of one or more tumour suppressor genes\textsuperscript{103}. Most ACCs do not acquire a large number of genetic changes, typical of other carcinomas\textsuperscript{104}. Over half of ACC cases present chromosome 6 deletions, suggesting an important selection for these alterations in the molecular aetiology of these neoplasms. However, efforts to identify a tumour suppressor gene at these loci in ACC have been unsuccessful to date\textsuperscript{103,105}.

MYB-NFIB is a putative oncoprotein, which has been shown to control ACC tumour cell proliferation and spherogenesis\textsuperscript{106}. Intriguingly, the fusion gene is regulated by AKT-dependent signalling downstream of the IGF1 receptor and its expression can be downregulated by IGF1R-inhibition with linsitinib. Furthermore, EGFR and MET signalling also promote growth of ACC cells\textsuperscript{106}. In line with these findings, evidence in patients or xenograft models indicate that monoclonal antibodies targeting IGF1 or EGF receptors could be effective drugs in ACCs expressing the fusion oncoprotein\textsuperscript{107–109}. To investigate the implication of the MYB-NFIB fusion gene in ACC, Mitani and co-workers analysed a cohort of 123 salivary carcinomas, including primary ACCs of the salivary gland, metastatic ACCs, non-ACC salivary carcinomas, and normal salivary gland tissues\textsuperscript{103}. Using RT-PCR, validated by fluorescence in situ hybridisation (FISH) analysis, they found that among 89 ACC cases (72 primary ACCs and

---

**Fig. 2 Schematic illustration of the MYB-NFIB fusion gene.** The t(6;9) translocation results in a MYB-NFIB gene fusion. Arrows indicate the breaking points.
17 metastatic), 26 were positive for expression of the MYB-NFIB fusion transcript. Interestingly, none of the 34 non-ACC carcinomas were positive. In addition, 14 different fusion transcripts involving multiple exons of MYB and NFIB were identified. To provide further insights on the role of MYB in this cancer, expression of the wild type or fusion MYB transcripts was quantified. Unsurprisingly, MYB expression was elevated in MYB-NFIB fusion positive ACCs, probably caused by loss of the negative regulatory sequence at the 3′ untranslated region of MYB. Interestingly, the expression of wild type MYB was elevated >40-fold in fusion-negative ACCs compared to non-ACC carcinomas, and only 2-fold lower than fusion-positive ACCs. The authors concluded that whereas genomic rearrangement must be causative of MYB overexpression in fusion positive ACCs, alternative mechanisms may be responsible for MYB overexpression in fusion negative ACCs. Thus, MYB overexpression is a frequent consequence of the MYB-NFIB fusion in glandular tumours, but can also occur via other mechanisms.

The polyether ionophore monensin was recently identified as a MYB inhibitor using a chemical screen in Zebrafish, suggesting that MYB inhibitors might be effective against liquid malignancies. Using a chemical screen in Zebrafish, the group of Leonard Zon have demonstrated that retinoic acid (ATRA) treatment of mice bearing patient-derived ACC tumours showed reduced expression of MYB and binding of MYB at translocated enhancers. Importantly, ATRA inhibited the expression of cell cycle related, MYB-target genes. ATRA is used in the clinic for the treatment of promyelocytic leukaemia and has a known safety profile, suggesting that it will be soon used in the context of a clinical trial in ACC patients.

Identification of actionable target genes downstream of MYB can be a reasonable alternative to avoid negative consequences caused by inactivation of the wild-type MYB transcription factor. Indeed, the potential haematologic toxicity of anti-MYB therapies could be further exacerbated in patients under regimens of chemotherapy and radiotherapy. An important gene axis regulated by MYB is the insulin growth factor and its receptor. Interestingly, insulin growth factor receptor (IGFR) signalling positively regulates MYB-NFIB in ACC, suggesting that MYB and IGFR are engaged in a feed forward loop in cancer. Accordingly, it has been shown that the small molecule inhibitor Linsitinib or the therapeutic antibody Figitumumab reduce the growth of ACC tumours in mouse models and in patients, suggesting that targeting IGFR signalling could be an effective strategy in MYB overexpressing cancers. In an effort to identify new MYB target genes in ACC, our group has generated retroviral vectors expressing wild-type MYB or two MYB-NFIB variants derived from ACC patients. The different MYB isoforms were ectopically expressed in immortalised breast MCF10A cells, and genes up or downregulated were identified by microarrays. GSEA revealed that ATR/BRCA was the top activated downstream pathway, with a significant upregulation of ATR gene expression. ATR mRNA levels were increased in primary ACCs compared to normal salivary glands. Accordingly, the clinical ATR kinase inhibitor VX-970 caused apoptosis of primary ACC cells in vitro and significant shrinkage of ACC patient-derived xenografts. These results support the theory that acting on downstream target genes/proteins might be a worthy — and even safer — alternative to directly targeting the MYB gene itself.

Surgery is the first line treatment for ACC, followed by cytotoxic chemotherapy and/or radiotherapy as adjuvant treatments to avoid recurrence. Unfortunately, standard treatments only provide limited benefit in advanced disease, which is usually lethal, with a high rate of recurrence and metastasis. Therefore, new and more effective treatments are urgently needed for these high-risk patients. Previous clinical trials have led to the approval of tyrosine kinase inhibitors (TKI) for the treatment of aggressive forms of solid malignancies, such as thyroid cancer refractory to radiotherapy and unresectable hepatocellular carcinoma. Most of the targeted tyrosine kinases are also MYB regulated, such as vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), the stem cell factor receptor KIT (c-KIT), FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptors (PDGFRs), and the proto-oncogene RET. Pernson and co-workers have recently shown that VEGFA, FGF2, KIT and other genes encoding receptor tyrosine kinases are commonly overexpressed in ACC samples, leading to consider TKIs as credible candidates for the treatment of relapsed/metastatic ACC patients. However, it has been observed an overall poor response in therapies against these targets in ACC, suggesting that other, more relevant MYB downstream genes should be clinically exploited in this tumour.

**MYBL1**

*MYBL1* is predominantly expressed in the central nervous system (CNS), germinal B-lymphocytes, mammary gland ductal epithelium, and in the testis. It has a key role in spermatogenesis, particularly in cell cycle
progression of germ cells through pachynema\textsuperscript{121,122}. \textit{MYBL1-null} mice are viable, but exhibit growth abnormalities as well as defects in spermatogenesis and female breast development\textsuperscript{120}.

\textbf{MYBL1 alterations in cancer}

\textit{MYBL1} rearrangements are a hallmark of low-grade gliomas (LGGs), the commonest paediatric CNS neoplasm, arising in children and adolescents\textsuperscript{114,123}. Recent molecular characterisations through WGS have led to the identification of new genetic alterations in LGGs. These studies have identified activation of the MAPK/ERK pathway caused by the duplication of the tyrosine kinase domain (TKD) of the \textit{FGFR1} gene and frequent rearrangements of the \textit{MYB} family members \textit{MYB} and \textit{MYBL1} in diffuse cerebral LGGs\textsuperscript{124}. 8q13.1 gain was observed as a significant recurrent event in diffuse astrocytoma grade IIs. This leads to a duplication of \textit{MYBL1} and truncation of its C-terminal NRD, resulting in anchorage-independent growth of NIH-3T3 cells and tumour formation in nude mice\textsuperscript{125}. \textit{MYBL1} gene amplification is a distinct alteration of the subtype IDH-wt/H3-wt of diffuse gliomas, together with \textit{TERT} and \textit{BRAF} mutations, \textit{EGFR} and \textit{FGFR1} alterations, and other chromosomal aberrations\textsuperscript{126}. Although these alterations are rare, sequencing analysis of uncommon low-grade neuro-epithelial tumours revealed that these pathogenic mutations occur at a high frequency (78\%) in this cohort\textsuperscript{114}.

Patients with isomorphic diffuse glioma or astrocytoma can harbour copy number alterations of \textit{MYBL1} or \textit{MYB} (13 out of 25 samples, 52\%), as assessed with RNA sequencing. Gene fusions accounted for 50\% of cases\textsuperscript{127}.

\textit{ACC} is characterised by the chromosomal translocation t(6;9), leading to the expression of the \textit{MYB-NFIB} fusion gene\textsuperscript{95}. Although \textit{MYB} is the \textit{MYB} family member most often involved in this cancer, it was recently demonstrated that a subset of \textit{ACC}s contains the t(8;9) chromosomal translocation\textsuperscript{128}. This results in the creation of a \textit{MYBL1-NFIB} gene fusion, which probably functions in a manner similar to \textit{MYB-NFIB}, given the structural analogies between \textit{MYBL1} and \textit{MYB}. Indeed, tumours with \textit{MYB} and \textit{MYBL1} translocations display overlapping gene expression profiles and clinical outcome, suggesting that the related \textit{MYB} proteins are interchangeable oncogenic drivers in \textit{ACC}. The research group that identified the translocation t(8;9), also highlighted a t(8;14) translocation, leading to the fusion of \textit{MYBL1} to the \textit{RADS1B} gene\textsuperscript{128}.

In \textit{MYB} or \textit{MYB-NFIB} negative subsets of breast \textit{ACC} tumours, alternative genetic mechanisms of \textit{MYB} activation have been demonstrated. RNA and WGS unveiled that these cancers could harbour \textit{MYBL1} rearrangements, including those between \textit{MYBL1-ACTN1} and \textit{MYBL1-NFIB}\textsuperscript{102}. In these rare triple negative breast cancers (TNBC), the histological pattern was identical to the \textit{MYB-NFIB}-positive, salivary gland \textit{ACC}s. The \textit{MYBL1} rearrangements were confirmed at genomic level by the FISH technique. The translocation results in an in-frame chimeric transcript containing the DNA-binding and transactivating domains, encoded by exons 1–14, of \textit{MYBL1} fused to the exon 9 of \textit{NFIB}. In addition, another in-frame fusion between \textit{MYBL1-ACTN1} was also detected for the first time in \textit{ACC} samples. The fusion leads to loss of the C-terminus region of \textit{MYBL1} due to the fusion of exons 1–8 of \textit{MYBL1} with exons 10–21 of \textit{ACTN1}\textsuperscript{102}.

Another organ in which \textit{ACC} neoplasms can originate is the lung. Primary tracheobronchial \textit{ACC} is one of the rarest types of lung cancer, accounting for <1\% of cases. Pei et al. analysed 7 lung \textit{ACC}s, documenting that 7 out of 7 cases presented \textit{MYB} or \textit{MYBL1} genes fused with \textit{NFIB} or, less frequently, with \textit{RAD51B}\textsuperscript{101}. Primary cutaneous \textit{ACC}s display a genetic landscape similar to those of salivary glands, showing fusions of either \textit{MYB} or \textit{MYBL1} with the common partner \textit{NFIB}\textsuperscript{129}.

\textbf{MYBL2}

\textit{MYBL2}, encoding the transcription factor \textit{MYBL2}, is ubiquitous and often co-expressed with other \textit{MYB} members. It has been shown to regulate cell cycle progression, cell survival and differentiation being an essential component of the DREAM complex\textsuperscript{130–133}. It is also a promoter of cell survival by activating antiapoptotic genes such as \textit{BIRC5} (survivin), \textit{CLU} (ApoJ/clusterin) and \textit{BCL2}\textsuperscript{134–137}. \textit{MYBL2} has been shown to aid repair of DNA double-strand breaks, supporting genome stability in haematopoietic and pluripotent stem cells\textsuperscript{138,139}. Expression of \textit{MYBL2} is important for both normal and transformed cell homeostasis. This concept is supported by the early embryonic lethal phenotype of \textit{MYBL2} knockout mice, due to impaired inner cell mass formation, or suppression of cell cycle progression and cell survival in oesophageal, hepatic, colorectal, and sympathetic nervous system cancer cells in which the expression of \textit{MYBL2} has been downregulated\textsuperscript{140–145}. The activity of \textit{MYBL2} is highly regulated at transcriptional and post-transcriptional levels. Cyclins and their catalytic partners, the cyclin-dependent kinases (Cdks), function as key regulators of the cell cycle\textsuperscript{146}. Cyclin D1 with Cdk4 or Cdk6 has been shown to play an important role at the ‘restriction point’ in the G1 phase of the cell cycle before cells enter into the mitotic cycle, whereas, for the transition from G1 to S phase, cyclin E–Cdk2 complexes are the most critical, and cyclin A–Cdk2 complexes are required during S phase\textsuperscript{146}. \textit{MYBL2} is regulated by the transcription factor E2F and required for the expression of cyclin B and cdc2 in G2/M\textsuperscript{147–149}. When overexpressed, the tumour suppressor protein p53 induces Waf1/Cip1/p21
protein-dependent cell-cycle arrest and activation of MYBL2 allows cells to escape this block, suggesting that MYBL2 acts at a later stage than Waf1/Cip1/p21 during cell-cycle progression\textsuperscript{150,151}. MYBL2 is a substrate for cyclin A/\(\text{A}\)/Cdk2 kinase activity and its transcriptional activity is regulated by phosphorylation\textsuperscript{148,150}. Genes involved in the G2/M phase of the cell cycle are activated by MYBL2 switching from the repressive DREAM to the MuvB (MMB) complex\textsuperscript{136,152,153}. MYBL2 is transcriptionally repressed in G1, activated by cyclin A/Cdk2-mediated phosphorylation during S-phase, and is transcriptionally repressed in G1, activated by cyclin A/E\textsuperscript{162}. Increased expression of several components of the MuvB (MMB) complexes is frequently perturbed in cancer\textsuperscript{159}. MYBL2 occurs at Serine or Threonine residues followed by Proline\textsuperscript{156}. Pin1 isomerase recognises the pSer/pThr-\(\text{MYBL2}\) occurs at Serine or Threonine residues followed by Proline\textsuperscript{156}. Pin1 isomerase recognises the pSer/pThr-

**MYBL2 alterations in cancer**

The DREAM complex [DP, RB-like, E2F4 and MuvB (synMuv genes, class B)] is a master coordinator of cell cycle-dependent gene expression and the balance between repressive DREAM and activating MYB-MuvB (MMB) complexes is frequently perturbed in cancer\textsuperscript{159–162}. Increased expression of several components of the MMB complex, including MYBL2 and FOXM1, correlates with aggressive tumour features and poor prognosis\textsuperscript{144,163}. To investigate the clinical relevance of the MYBL2/FOXM1/CDK/PLK1 axis, Werwein et al. used a pan-cancer resource of expression signatures that correlate cancer gene expression and clinical diagnosis data, called PRECOG\textsuperscript{157}. Interestingly, among the 50 genes (and their products) analysed, 44 (including MYBL2, FOXM1, CCNA2, and PLK1) were found to be targets of DREAM-mediated repression, while 29 of them were also targets of MMB activation\textsuperscript{157}. Overexpression of MYBL2 disturbs myeloid differentiation and promotes the progression of solid cancers where it is also an indicator of poor prognosis\textsuperscript{133,142,164–166}. MYBL2 is frequently overexpressed in malignancies including breast cancer, non-small-cell lung cancer (NSCLC), AML, colorectal cancer, pancreatic ductal adenocarcinoma, and neuroblastoma\textsuperscript{167–175}.

The molecular mechanisms causing increased expression of MYBL2 in multiple human cancers are still not fully elucidated.

**MYBL2 and breast cancer** Alterations of gene expression might be caused by amplification of the MYBL2 locus located in chromosome 20q13\textsuperscript{176–178}. 20q13 amplification or copy gains are common in breast cancer and are usually associated with poor prognosis\textsuperscript{176}. Notably, a MYBL2 germine polymorphism causing the Serine-to-Glycine amino acid change S427G is correlated to a high risk of basal-like breast cancer\textsuperscript{133}. Moreover, MYBL2 overexpression was noted in HER2+/\(\text{ER}–\) and luminal B breast cancer samples, but not in luminal A or normal breast tissue, strongly suggesting a correlation between MYBL2 expression and aggressiveness of breast cancer\textsuperscript{177}. A recent review explains the molecular mechanisms of MYBL2 amplification and new therapeutic opportunities in breast cancers\textsuperscript{179}.

**MYBL2, clear cell renal cell carcinoma (ccRCC) and NSCLC** ccRCC is the most frequent renal malignancy\textsuperscript{180}. MYBL2 expression could be used as a biomarker to predict patients’ prognosis in this cancer. MYBL2 expression and worse prognosis was established by Kaplan–Meier analysis, indicating that MYBL2 expression is an independent biomarker of progression in ccRCC\textsuperscript{181}. Another neoplasia characterised by deregulation of MYBL2 is non-small-cell lung cancer (NSCLC). Analysis of MCODE clusters highlighted genes involved in “driver networks” for NSCLC, which include the transcription factors FOXM1, TFDPI, E2F4, SIN3, and MYBL2\textsuperscript{182}. A further study confirmed the potential oncogenic role of MYBL2 in NSCLC. Through chromatin immunoprecipitation (ChIP) assay, researchers identified a direct binding between MYBL2 and the gene \textit{Non-SMC Condensin Complex Subunit H (NCAPH)}, well-known to have oncogenic properties in lung cancer. A significant correlation between high NCAPH expression and poor prognosis was confirmed, suggesting that targeting the MYBL2-regulated gene could be of potential therapeutic value in this setting\textsuperscript{169}.

**MYBL2 and leukaemia** MYBL2 overexpression is a prognostic factor in AML, defining a subset of patients with poor prognosis\textsuperscript{170,183}. This could be linked to the reduced expression of miR-30a, miR-30b and miR-30c, involved in the regulation of haematopoiesis and cell
differentiation, which were shown to be expressed at lower levels in MYBL-high AML samples. The strong correlation between overexpression of MYBL2 and downregulation of the miR-30 cluster suggests that the miR-30 cluster suppresses tumour progression. PP2A is thought to be repressed by Myb.

A recent study published in Cell revealed a link between MYBL2 and the protein phosphatase 2A (PP2A) in leukaemia. Morita and co-workers identified a class of small molecule that they called iHAPs—improved heterocyclic activators of PP2A—able to activate a PP2A complex, which suppresses tumour progression. PP2A is an enzyme formed by different subunits; among them, PPP2R1A, PPP2CA, and PPP2R5E are strictly required for antitumor activity. Using isotope-labelled amino acids (SILAC) and mass spectrometry analysis, substrates dephosphorylated by PP2A in the presence or absence of iHAPs were identified, among which MYBL2. The researchers were able to activate the PP2A complex, usually present in an inactive form in cancers due to the overexpression of inhibitory proteins, and observe dephosphorylation of MYBL2 on Ser241, required for transactivation of cell cycle-related genes, resulting in an irreversible growth arrest of multiple cancer cells. Thus, MYBL2 is centrally involved in cancer cell proliferation and can be indirectly targeted by small molecule-mediated reactivation of the PP2A tumour suppressor protein.

Conclusions

The MYB transcription factors are a point of convergence of numerous signalling pathways essential for multiple cellular functions, and their deregulation has been associated with aggressive behaviour of cancer cells. Reflecting the high similarity of protein structures, MYBL1, MYBL2, and MYB are all involved in the control of cell survival, proliferation and differentiation. One could hypothesise that spatio-temporal differences in gene expression during organogenesis and in pathological conditions may determine specific MYB requirements in cells. The ever-expanding number of studies reporting deregulation of MYB family members in the pathogenesis of human cancers is instigating researchers to find new and more efficient methods to target these transcription factors. Direct pharmacological inhibition of MYB or its product MYB, is emerging as a potential therapeutic strategy for both liquid and solid malignancies. Nevertheless, inhibiting MYB could potentially lead to haematopoietic toxicity, indicating that targeting downstream target genes and coactivator molecules might make more clinical sense. Further studies will be required to develop effective therapeutic interventions aiming at suppressing MYB signalling in tumours while minimising risks to patients.

Acknowledgements

Y.C. and A.S. are supported by a grant from the Oracle Cancer Trust.

Conflict of interest

The authors declare no competing interests.

References

1. Lippsich, J. S. & Wang, D. M. Transformation by v-Myc. Oncogene 18, 3047–3055 (1999).
2. Roussel, M. et al. Three new types of viral oncogene of cellular origin specific for hematopoietic cell transformation. Nature 281, 452–455 (1979).
3. Hall, W. J., Bean, C. W. & Pollard, M. Transmission of fowl leukosis through chick embryos and young chicks. Am. J. Vet. Res. 2, 272–279 (1941).
4. Boyle, W. J., Lippsich, J. S., Reddy, E. P. & Baluda, M. A. Identification of the leukemogenic protein of avian myeloblastosis virus and of its normal cellular homologue. Proc. Natl Acad. Sci. USA 80, 2864–2868 (1983).
5. Westin, E. H. et al. Differential expression of the avm gene in human hematopoietic cells. Proc. Natl Acad. Sci. USA 79, 2194–2198 (1982).
6. Nunn, M. F., Seeberg, P. H., Moscovic, C. & Duesberg, P. H. Tripartite structure of the avian erythroblastosis virus E26 transforming gene. Nature 306, 391–395 (1983).
7. Davidson, C. J., Tiouvanazam, R., Herzenberg, L. A. & Lippsich, J. S. Functional evolution of the vertebrate Myb gene family: B-Myb, but neither A-Myb nor c-Myb, complements Drosophila Myb in hemocytes. Genetics 169, 215–229 (2000).
8. Lippsich, J. S. The C-Myb story—is it definitive? Proc. Natl Acad. Sci. USA 107, 17067–17068 (2010).
9. Lippsich, J. S. et al. Functional evolution of the Myb oncogene family. Blood Cells Mol. Dis. 27, 456–458 (2001).
10. Ohi, R. et al. Myb-related Schizosaccharomyces pombe cdc5p is structurally and functionally conserved in eukaryotes. Mol. Cell. Biol. 18, 4097–4108 (1998).
11. Ohi, R. et al. Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities. Mol. Cell 28, 2091–2101 (2008).
12. Ramsay, R. G. & Gonda, T. J. Myb function in normal and cancer cells. Nat. Rev. Cancer 8, 523–534 (2008).
13. Ogata, K. et al. Solution structure of a DNA-binding unit of Myb: a helix-turn-helix-related motif with conserved tryptophans forming a hydrophobic core. Proc. Natl Acad. Sci. USA 89, 6428–6432 (1992).
14. Biedenkapp, H., Borrmeyer, U., Sippel, A. E. & Klempnauer, K. H. Vital myb oncogene encodes a sequence-specific DNA-binding activity. Nature 335, 855–857 (1988).
15. Ess, S. A., Marknell, A. & Graf, T. The v-myc oncogene product binds to and activates the promyelocytic-cyte-specific mim-1 gene. Cell 59, 1115–1125 (1989).
16. Quntana, A. M., Liu, F., O’Rourke, J. P. & Ness, S. A. Identification and regulation of c-Myb target genes in MCF-7 cells. J. Mol. Biol. 11, 30 (2011).
17. Zhao, L. et al. Integrated genome-wide chromatin occupancy and expression analyses identify key myeloid pro-differentiation transcription factors repressed by Myb. Nucleic Acids Res. 39, 4664–4670 (2011).
18. Dai, P. et al. CBP as a transcriptional coactivator of c-Myb. Genes Dev. 10, 528–540 (1996).
19. Oelgeschlager, M., Janknecht, R., Krieg, J., Schreek, S. & Luscher, B. Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M. EMBO J. 15, 2771–2780 (1996).
23. Oelgeschlager, M., Kowenz-Leutz, E., Schree, K., Leutz, A. & Luscher, B. Tumorigenic N-terminal deletions of c-Myb modulate DNA binding, transactivation, and cooperativity with CEBP. Oncogene 20, 7420–7424 (2001).

24. Mirk, S., Kerber, U. & Klempnauer, K. H. Interaction of CEBPBeta and v-Myb is required for synergistic activation of the mmm-1 gene. Mol. Cell. Biol. 16, 1316–1325 (1996).

25. Shapiro, L. H. Myb and Ets proteins cooperate to transactivate an early myeloid gene. J. Biol. Chem. 270, 8763–8771 (1995).

26. Bartunik, P., Kralova, J., Blendinger, G., Dvořák, M. & Zelenk, M. GATA-1 and c-Myb crossstalk during red blood cell differentiation through GATA-1 binding sites in the c-myc promoter. Oncogene 22, 1927–1935 (2003).

27. Mansour, M. R. et al. Oncogene regulation. An oncogenic super-enhancer involving of interleukin-33 and nerve growth factor receptors. J. Pathol. 242, 347–357 (2017).

28. Magier, L. F. et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J. Clin. Investig. 125, 2579–2591 (2015).

29. Bailly, R. A. et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol. Cell. Biol. 14, 3230–3241 (1994).

30. Elazer, S., Spencer, J., Ye, D., Olsin, E. & Ilaria, R. L. J. Arteriation of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing’s sarcoma. Mol. Cell. Biol. 23, 482–492 (2003).

31. Schoch, C. et al. Twenty-three cases of acute lymphoblastic leukemia with t(11;22)(q24;q12): the implication of additional chromosomal aberrations. Ann. Hematol. 70, 195–201 (1995).

32. Schwartz, J. C., Cech, T. R. & Parker, R. R. Biochemical properties and biological functions of FET proteins. Annu. Rev. Biochem. 84, 355–379 (2015).

33. Pien, T. et al. MYB deregulation from a EWSR1-MYB fusion at leukemic blasts in a patient with primary myelofibrosis: long-range MYB brackets. Blood 118, 3470–3479 (2011).

34. Malaterre, J. et al. c-Myb is required for progenitor cell proliferation and maintenance of the neural stem cell niche in adult brain. Nat. Neurosci. 25, 275–286 (2016).

35. Kastan, M. B., Slamon, D. J. & Civan, C. I. Expression of protooncogene c-myc in normal human hematopoietic cells. Blood 73, 1444–1451 (1989).

36. Ess, K. C., Witte, D. P., Bascomb, C. P. & Aronov, B. J. Diverse developing mouse lineages exhibit high-level c-myc expression in immature cells and loss of expression upon differentiation. Oncogene 10, 1103–1111 (1991).

37. Malaterre, J. et al. c-Myb is required for neural progenitor cell proliferation and maintenance of the neural stem cell niche in adult brain. Stem Cells 26, 173–181 (2008).

38. Malaterre, J. et al. c-Myb controls autoregulation of c-Myb expression via Myb binding sites in the flanking region of the human cdc2 gene. J. Biol. Chem. 282, 168–174 (2007).

39. Pilkinton, M., Sandoval, R., Song, J. & Ness, S. A. Positive and negative regulation of c-Myb by CDK1.

40. Lei, W., Liu, F. & Ness, S. A. Positive and negative regulation of c-Myb by CDK1.

41. Bandopadhayay, P. et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J. Clin. Investig. 118, 1739–1749 (2008).

42. Yang, G. et al. RNA-binding protein quaking, a critical regulator of colon cancer stemness and antitumor immunity. Stem Cells Transl. Med. 8, 236–241 (2019).

43. Estey, E. H. Acute myeloid leukemia: 2007 update on risk-stratiﬁcation and management. Blood 112, 2976–2984 (2008).

44. Mellinger, L. T., Dessen, P. & Bemheim, A. An atlas of chromosomese in hematological malignancies. Example: 11q23 and MLL partners. Leukemia 15, 987–989 (2001).

45. Meyer, C. et al. The MLL rearricomine of acute leukemias. Leukemia 20, 777–784 (2006).

46. Hess, J. L. et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 108, 297–304 (2006).

47. Pataabiram, D. R. et al. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. Blood 123, 2682–2690 (2014).

48. Uttarkar, S. et al. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. Blood 127, 1173–1182 (2016).

49. Uttarkar, S. et al. Naphthol AS-E phosphate inhibits the activity of the transcription factor Myb by blocking the interaction with the RIX domain of the coactivator p300. Mol. Cancer Ther. 14, 1276–p1285 (2015).

50. Quelen, C. et al. Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. Blood 117, 5719–5722 (2011).

51. Belloni, E. et al. In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels. Leukemia 25, 733–736 (2011).

52. Ducassou, S. et al. MYB-GATA1 fusion promotes basophilic leukemia: involvement of interleukin-33 and nerve growth factor receptors. J. Pathol. 242, 347–357 (2017).

53. Soignet, S. L. et al. Microsatellite instability and epigenetic mechanisms mediate tumor development and progression in glioblastoma multiforme. Cell Cycle 5, 783–791 (2006).

54. Ichimura, K. et al. Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH. Oncogene 25, 1261–1271 (2006).
Fehr, A. et al. The MYB-NFIB gene fusion—a novel genetic link between oncogenesis and metastasis.

Cicirò and Sala 2021

Pei, J. et al. Detecting MYB and MYBL1 fusion genes in tracheobronchial adenoid cystic carcinoma by targeted RNA-sequencing. Mod. Pathol. 32, 1416–1420 (2019).

Kim, J. et al. MYB1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. J. Pathol. 244, 143–150 (2008).

Mitani, Y. et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin. Cancer Res. 16, 4722–4731 (2010).

Ho, A. S. et al. The mutational landscape of adenoid cystic carcinoma. Nat. Genet. 45, 791–798 (2013).

Rutherford, S. et al. The relationship between MYB and MYBL1 in breast and salivary gland adenoid cystic carcinoma. Cancer Lett. 323, 309–317 (2006).

Andersen M. K. et al. Andren Y., Wick M. J. & Stenman G. Targeting the oncogenic transcriptional regulator MYB in adenoid cystic carcinoma by inhibition of IGFR/RAK signaling. Nat. Cell Biol. 109, (2017).

Morell, M. P. et al. Prioritizing phase I treatment options through preclinical modeling of personalized tumors. J. Clin. Oncol. 38, 97–104 (2020).

Mahadevan, D. et al. Phase I study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother. Pharmacol. 75, 467–473 (2014).

Calvo, E. et al. Phase I clinical trial and independent patient-derived xenograft study of combined targeted treatment with cabozantinib and figlituzumab in advanced solid tumors. Clin. Cancer Res. 23, 1177–1187 (2017).

Yusenko, M. V. et al. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells. Cancer Lett. 479, 61–70 (2020).

Mandelbaum, J. et al. Zebratinib blasticorese screen identifies retinoic acid suppression of c-Myc-MD-Vegf (c-MYB) in adenoid cystic carcinoma. J. Exp. Med. 210, 2673–2688 (2018).

Andersen K. M., Afshari M. K., Andren Y., Wick M. J. & Stenman G. Targeting the oncogenic transcriptional regulator MYB in adenoid cystic carcinoma by inhibition of IGFR/RAK signaling. Nat. Cell Biol. 109, 1687–1717 (2005).

Golub, M. A. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Galien International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 22, 2226–2223 (2013).

Yang, R. M. et al. MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells. Oncogene 38, 5239–5249 (2019).

Miao, R. Y. et al. MYB is essential for mammary tumorigenesis. Cancer Res. 71, 7057–7057 (2011).

Early Breast Cancer Trialists' Collaborative G. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 787–794 (2011).

Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).

Early Breast Cancer Trialists’ Collaborative G. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386, 1341–1352 (2015).

Mitra, P., Yang, R. M., Sutton, J., Ramsay, R. G. & Gonda, Y. T. CD95 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression. Oncotarget 7, 9069–9083 (2016).

Ward, A. et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 32, 1173–1182 (2013).

Kopral, M., Lee, E. S., Hu, G. & Kang, Y. The mR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283, 14910–14914 (2008).

Park, S. M., Gaur, A. B., Lengyel, E. & Peter, M. E. The mR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894–907 (2008).

Gao, Y., Zhang, W., Liu, C. & Li, G. mR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB. Sci. Rep. 9, 16899 (2019).

Persson, M. et al. Recurrent fusion of MYB and NFB transcription factor genes in breast cancer. Proc. Natl Acad. Sci. USA 104, 18740–18744 (2009).

Brill, L. B. et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod. Pathol. 24, 1169–1176 (2011).

Togashi, Y. et al. MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts. Mod. Pathol. 31, 934–946 (2018).

Magers, M. J. et al. MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. Mod. Pathol. 32, 1666–1674 (2019).

Dier, Y. et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat. Genet. 52, 265–272 (2016).

Feby, A. et al. The MYB-NFIB genomic fusion - a novel genetic link between adenoid cystic carcinoma and dermal cylindroma. J. Pathol. 224, 322–327 (2011).
126. Ellison, D. W. et al. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol. 137, 683–687 (2019).

127. Weifers, A. K. et al. Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYB or MYB and a benign disease course. Acta Neuropathol. 139, 193–209 (2020).

128. Beyer, K. J., Fresch, C. A., Kang, H. & Ness, S. A. Recurrent fusions in MYB and MYBL1 define a common, transcription factor-driven oncogenic pathway in salivary gland adenoid cystic carcinoma. Cancer Discov. 6, 176–187 (2016).

129. Kypychova, L. et al. Small subset of adenoid cystic carcinoma of the skin is associated with alterations of the MYBL1 gene similar to its extratumoral counterparts. Am. J. Dermatopathol. 40, 721–726 (2018).

130. Iness, A. N. et al. The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb. Oncogene 38, 1080–1092 (2019).

131. Sala, A. et al. Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. Proc. Natl Acad. Sci. USA 99, 10415–10419 (2002).

132. Santilli, G. et al. Temperature-dependent modification and activation of B-MYB are essential for normal cell cycle progression and chromosomal stability of embryonic stem cells. PLoS ONE 3, e2478 (2008).

133. Sadasivam, S., Duan, S. & DeCaprio, J. A. The MuBx complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev. 26, 474–489 (2012).

134. Wolfert, A. K. et al. Isomorphid diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYB or MYB and a benign disease course. Acta Neuropathol. 139, 193–209 (2020).

135. Qin, H. et al. Prognostic implications and oncogenic roles of MYBL2 protein in colorectal cancer. Acta Neuropathol. 129, 551–568 (2019).

136. Raschella, G. et al. Requirement of b-myb function for survival and differentiation of human neuroblastoma cell lines. Cancer Res. 56, 2451–2456 (1996).

137. Wolter, P., Hanselmann, S., Schruff, E. & Gaubatz, S. Central spindle proteins and mitotic kinesins are direct transcriptional targets of MYBL2, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy. Oncotarget 8, 11160–11172 (2017).

138. Chen, J. & Chen, X. MYBL2 is targeted by miR-143-3p and regulates breast cancer cell proliferation and apoptosis. Oncol. Res. 26, 913–922 (2018).

139. Jin, Y. et al. B-Myb is up-regulated and promotes cell growth and motility in non-small cell lung cancer. Int. J. Mol. Sci. 18, 860 (2017).

140. Xiong, Y. C., Wang, J., Cheng, Y., Zhang, X. Y. & Ye, X. Q. Overexpression of MYBL2 promotes proliferation and migration of non-small cell lung cancer cell lines: a basis for interpreting complementary DNA microarray data. Oncotarget 8, 2705–2706 (2017).

141. Foster, O. et al. Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients. Leuk. Res. 37, 1690–1696 (2013).

142. Ribeiro, P. et al. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancies. Br. J. Haematol. 168, 423–433 (2015).

143. Yu, R. et al. Clinico-pathologic features and prognostic implications of MYBL2 protein expression in prostate cancer cell lines. J. Mammary Gland Biol. Neoplasia 20, 177–185 (2015).

144. Raschella, G. et al. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. Cancer Res. 59, 3365–3368 (1999).

145. Shi, H. et al. Single nucleotide polymorphisms in the 20q13 ampiclon genes in relation to breast cancer risk and clinical outcome. Breast Cancer Res. Treat. 130, 905–916 (2011).

146. Tanner, M. M. et al. Frequent amplification of chromosomal region 20q12-21 in ovarian cancer. Clin. Cancer Res. 6, 1833–1839 (2000).

147. Forozan, F. et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res. 60, 4519–4525 (2000).

148. Bayley, R., Wang, C. & Garcia, P. MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential. Biochim. Biophys. Acta Rev. Cancer 1874, 188407 (2020).
180. Ljunghberg, B. et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur. Urol. 75, 799–810 (2019).
181. Sun, S. S., Fu, Y. & Lin, J. Y. Upregulation of MYB2 independently predicts a poorer prognosis in patients with clear cell renal cell carcinoma. Oncol. Lett. 19, 2765–2772 (2020).
182. Ahmed, F. Integrated network analysis reveals FOXM1 and MYB2 as key regulators of cell proliferation in non-small cell lung cancer. Front. Oncol. 9, 1011 (2019).
183. Clarke, M. et al. MYB2 haploinsufficiency increases susceptibility to age-related haematoepoietic neoplasias. Leukemia 27, 661–670 (2013).
184. Chen, C. Z., Li, L., Lodish, H. F. & Bartel, D. P. MicroRNAs modulate hematopoietic lineage differentiation. Science 303, 85–86 (2004).
185. Cammarata, G. et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Ann. J. Hematol. 85, 331–339 (2010).
186. Morita, K. et al. Allosteric activators of protein phosphatase 2A display broad antitumor activity mediated by dephosphorylation of MYB2. Cell 181, 702–715 e720 (2020).
187. Leverson, J. D. & Ness, S. A. Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanism. Mol. Cell 1, 203–211 (1998).
188. Introna, M. et al. Mutations in v-myb alter the differentiation of myelomonocytic cells transformed by the oncogene. Cell 63, 1289–1297 (1990).
189. Takahashi, T. et al. Inhibitory interaction of c-Myb and GATA-1 via transcriptional co-activator CBP. Oncogene 19, 134–140 (2000).
190. Rushton, J. J. & Ness, S. A. The conserved DNA binding domain mediates similar regulatory interactions for A-Myb, B-Myb, and c-Myb transcription factors. Blood Cells Mol. Dis. 27, 459–463 (2001).
191. Bergholtz, S. et al. The highly conserved DNA-binding domains of A-, B- and c-Myb differ with respect to DNA binding, phosphorylation and redox properties. Nucleic Acids Res. 29, 3546–3556 (2001).
192. Luscher, B., Christenson, E., Litchfield, D. W., Kiebs, E. G. & Eisenman, R. N. Myb DNA binding inhibited by phosphorylation at a site deleted during oncogenic activation. Nature 344, 517–522 (1990).
193. Cervellera, M. N. & Sala, A. Poly(ADP-ribose) polymerase is a B-Myb coactivator. J. Biol. Chem. 275, 10692–10696 (2000).
194. Bies, J., Markus, J. & Wolff, L. Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-myb transcription factor modifies its stability and transcriptional activity. J. Biol. Chem. 277, 8999–9009 (2002).
195. Sano, Y. & Ishii, S. Increased affinity of c-Myb for CREB-binding protein (CBP) after CBP-induced acetylation. J. Biol. Chem. 276, 3674–3682 (2001).
196. Aziz, N. et al. Modulation of c-Myb-induced transcription activation by a phosphorylation site near the negative regulatory domain. Proc. Natl Acad. Sci. USA 92, 6429–6433 (1995).
197. Tomita, A. et al. c-Myb acetylation at the carboxy-terminal conserved domain by transcriptional co-activator p300. Oncogene 19, 444–451 (2000).
198. Frampont, J., Ramqvist, T. & Graf, T. v-Myb of E26 leukemia virus up-regulates bcl-2 and suppresses apoptosis in myeloid cells. Genes Dev. 10, 2720–2731 (1996).
199. Salamoni, P., Perrotti, D., Martinez, R., Franceschi, C. & Calabretta, B. Resistance to apoptosis in CTL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb-dependent regulation of bcl-2 promoter activity. Proc. Natl Acad. Sci. USA 94, 3296–3301 (1997).
200. Zhou, F., Zhang, L., von Laar, T., van Dam, H. & Ten Dijke, P. GSK3beta inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb. Mol. Biol. Cell 22, 3533–3540 (2011).
201. Down, C. F., Millour, J., Lam, E. W. & Watson, R. J. Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. Biochim. Biophys. Acta 1819, 855–862 (2012).
202. Osterloh, L. et al. The human synMux-like protein LIN-9 is required for transcription of G2/M genes and for entry into mitosis. EMBO J. 26, 145–157 (2007).
203. Okada, M., Aikiuyama, H., Hou, D. X., Takahashi, T. & Ishii, S. Myb controls G2/M progression by inducing cyclin B expression in the Drosophila eye imaginal disc. EMBO J. 21, 675–684 (2002).
204. Bartusel, T., Schubert, S. & Klemmepner, K. H. Regulation of the cyclin D1 and cyclin A1 promoters by B-Myb is mediated by Sp1 binding sites. Gene 351, 171–180 (2005).
205. Srivastava, S. K. et al. Myb overexpression overrides androgen depletionalso-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis 33, 1149–1157 (2012).
206. Cheasley, D. et al. Defective Myb function ablates cyclin E1 expression and perturbs intestinal carcinogenesis. Mol. Cancer Res. 13, 1185–1196 (2015).
207. Siu, G., Wurster, A. L., Lipsick, J. S. & Hedrick, S. M. Expression of the CD4 gene requires a Myb transcription factor. Mol. Cell. Biol. 12, 1592–1604 (1992).
208. Melotto, P., Ku, D. H. & Calabretta, B. Regulation of the expression of the hematopoietic stem cell antigen CD34: role of c-myc. J. Exp. Med. 179, 1023–1028 (1994).
209. Ma, X. P. & Calabretta, B. DNA binding and transcriptional activation of A-myc, a c-myc-related gene. Cancer Res. 54, 6512–6516 (1994).
210. Papetti, M. & Augenlicht, L. H. MYB2, a link between proliferation and differentiation in maturing colon epithelial cells. J. Cell. Physiol. 226, 785–791 (2011).
211. De Dominici, M. et al. Targeting CDK6 and BCL2 Exploits the “MYB Addiction” of PhI(+) acute lymphoblastic leukemia. Cancer Res. 78, 1097–1109 (2018).
212. Frau, M. et al. Myb2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype. J. Hepatol. 55, 111–119 (2011).
213. Liu, F., Lei, W., O’Rourke, J. P. & Ness, S. A. Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-myc. Oncogene 25, 795–805 (2006).
214. Hogg, A. et al. Inactivation of a c-Myb/estrogen receptor fusion protein in transformed primary cells leads to granulocyte/macrophage differentiation and down regulation of c-kit but not c-myc or cdc2. Oncogene 15, 2885–2898 (1997).
215. Ratajczak, M. Z. et al. Myb and ets proteins are candidate regulators of c-kit expression in human hematopoietic cells. Blood 91, 1934–1946 (1998).
216. Duddek, H., Tantravahi, R. V., Rao, V N, Reddy, E. S. & Reddy, E. P. Myb and Ets proteins cooperate in transcriptional activation of the mim-1 promoter. Proc. Natl Acad. Sci. USA 89, 1291–1295 (1992).
217. Wilczek, C., Chayka, O., Plachetka, A. & Klemmepner, K. H. Myb-induced chromatin remodelling at a dual enhancer/promoter element involves non-coding m RNA transcription and is disrupted by oncogenic mutations of v-myb. J. Biol. Chem. 284, 35314–35324 (2009).
218. Nakagoshi, H., Kane-Ishii, C., Sawazaki, T., Mzuguichi, G. & Ishii, S. Transcriptional activation of the c-myc gene by the c-myc and B-myb gene products. Oncogene 7, 1233–1240 (1992).